Medication Reviews—The Good, The Bad, and The Baffling Managing multiple medication: What do I want from you? by Sam Barnett-Cormack Tackling Polypharmacy: Stopping Medicines Safely (July 2017)
NR 508 Inspiring Innovation/tutorialrank.comjonhson143
For more course tutorials visit
www.tutorialrank.com
Discussion Part One
Emily, a relatively healthy 5’5”, 32-year-old young woman weighing 190 pounds, presents to your clinic with hirsutism, anovulation, oligomenorrhea, and at times amenorrhea. Biochemical blood tests reveal elevated luteinizing hormone (LH, without a mid-cycle surge) and androgen elevation.
NR 508 Education Specialist / snaptutorial.comMcdonaldRyan149
For more classes visit
www.snaptutorial.com
Discussion Part One
Emily, a relatively healthy 5’5”, 32-year-old young woman weighing 190 pounds, presents to your clinic with hirsutism, anovulation, oligomenorrhea, and at times amenorrhea. Biochemical blood tests reveal elevated luteinizing hormone (LH, without a mid-cycle surge) and androgen elevation.
She mentions that she also has a family history of irregular cycles, and that her grandmother experienced early
Nr 508 Education Organization / snaptutorial.comBaileya135
For more classes visit
www.snaptutorial.com
Discussion Part One
Emily, a relatively healthy 5’5”, 32-year-old young woman weighing 190 pounds, presents to your clinic with hirsutism, anovulation, oligomenorrhea, and at times amenorrhea. Biochemical blood tests reveal elevated luteinizing hormone (LH, without a mid-cycle surge) and androgen elevation.
This a project for a high school AP Psychology course. This is a fictionalized account of having a psychological ailment. For questions about this blog project or its content please email the teacher, Laura Astorian: laura.astorian@cobbk12.org
NR 508 Inspiring Innovation/tutorialrank.comjonhson143
For more course tutorials visit
www.tutorialrank.com
Discussion Part One
Emily, a relatively healthy 5’5”, 32-year-old young woman weighing 190 pounds, presents to your clinic with hirsutism, anovulation, oligomenorrhea, and at times amenorrhea. Biochemical blood tests reveal elevated luteinizing hormone (LH, without a mid-cycle surge) and androgen elevation.
NR 508 Education Specialist / snaptutorial.comMcdonaldRyan149
For more classes visit
www.snaptutorial.com
Discussion Part One
Emily, a relatively healthy 5’5”, 32-year-old young woman weighing 190 pounds, presents to your clinic with hirsutism, anovulation, oligomenorrhea, and at times amenorrhea. Biochemical blood tests reveal elevated luteinizing hormone (LH, without a mid-cycle surge) and androgen elevation.
She mentions that she also has a family history of irregular cycles, and that her grandmother experienced early
Nr 508 Education Organization / snaptutorial.comBaileya135
For more classes visit
www.snaptutorial.com
Discussion Part One
Emily, a relatively healthy 5’5”, 32-year-old young woman weighing 190 pounds, presents to your clinic with hirsutism, anovulation, oligomenorrhea, and at times amenorrhea. Biochemical blood tests reveal elevated luteinizing hormone (LH, without a mid-cycle surge) and androgen elevation.
This a project for a high school AP Psychology course. This is a fictionalized account of having a psychological ailment. For questions about this blog project or its content please email the teacher, Laura Astorian: laura.astorian@cobbk12.org
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
NR 508 Enhance teaching - snaptutorial.comDavisMurphyA60
For more classes visit
www.snaptutorial.com
Discussion Part One
Emily, a relatively healthy 5’5”, 32-year-old young woman weighing 190 pounds, presents to your clinic with hirsutism, anovulation, oligomenorrhea, and at times amenorrhea. Biochemical blood tests reveal elevated luteinizing hormone (LH, without a mid-cycle surge) and androgen elevation.
Nr 508 Education Organization -- snaptutorial.comDavisMurphyC7
For more classes visit
www.snaptutorial.com
Discussion Part One
Emily, a relatively healthy 5’5”, 32-year-old young woman weighing 190 pounds, presents to your clinic with hirsutism, anovulation, oligomenorrhea, and at times amenorrhea. Biochemical blood tests reveal elevated
Nr 508 Education Redefined-snaptutorial.comrobertledwes48
For more classes visit
www.snaptutorial.com
Discussion Part One
Emily, a relatively healthy 5’5”, 32-year-old young woman weighing 190 pounds, presents to your clinic with hirsutism, anovulation, oligomenorrhea, and at times amenorrhea. Biochemical blood tests reveal elevated luteinizing hormone (LH, without a mid-cycle surge) and androgen elevation.
NR 508 Effective Communication - tutorialrank.comBartholomew49
For more course tutorials visit
www.tutorialrank.com
Discussion Part One
Emily, a relatively healthy 5’5”, 32-year-old young woman weighing 190 pounds, presents to your clinic with hirsutism, anovulation, oligomenorrhea, and at times amenorrhea. Biochemical blood tests reveal elevated luteinizing hormone (LH, without a mid-cycle surge) and androgen elevation.
For this Discussion, review the case Learning Resources and the DustiBuckner14
For this Discussion, review the case Learning Resources and the case study excerpt presented. Reflect on the case study excerpt and consider the therapy approaches you might take to assess, diagnose, and treat the patient’s health needs.
Case: An elderly widow who just lost her spouse.
Subjective: A patient presents to your primary care office today with chief complaint of insomnia. Patient is 75 YO with PMH of DM, HTN, and MDD. Her husband of 41 years passed away 10 months ago. Since then, she states her depression has gotten worse as well as her sleep habits. The patient has no previous history of depression prior to her husband’s death. She is awake, alert, and oriented x3. Patient normally sees PCP once or twice a year. Patient denies any suicidal ideations. Patient arrived at the office today by private vehicle. Patient currently takes the following medications:
•
Metformin 500mg BID
•
Januvia 100mg daily
•
Losartan 100mg daily
•
HCTZ 25mg daily
•
Sertraline 100mg daily
Current weight: 88 kg
Current height: 64 inches
Temp: 98.6 degrees F
BP: 132/86
By Day 3 of Week 7
Post
a response to each of the following:
• List three questions you might ask the patient if she were in your office. Provide a rationale for why you might ask these questions.
• Identify people in the patient’s life you would need to speak to or get feedback from to further assess the patient’s situation. Include specific questions you might ask these people and why.
• Explain what, if any, physical exams, and diagnostic tests would be appropriate for the patient and how the results would be used.
• List a differential diagnosis for the patient. Identify the one that you think is most likely and explain why.
• List two pharmacologic agents and their dosing that would be appropriate for the patient’s antidepressant therapy based on pharmacokinetics and pharmacodynamics. From a mechanism of action perspective, provide a rationale for why you might choose one agent over the other.
• For the drug therapy you select, identify any contraindications to use or alterations in dosing that may need to be considered based on the client’s ethnicity. Discuss why the contraindication/alteration you identify exists. That is, what would be problematic with the use of this drug in individuals of other ethnicities?
• Include any “check points” (i.e., follow-up data at Week 4, 8, 12, etc.), and indicate any therapeutic changes that you might make based on possible outcomes that may happen given your treatment options chosen.
Respond to the these discussions. All questions need to be addressed.
Discussion 1 En
Three questions to ask the patient and a rationale for asking these questions.
How may I be of assistance today? This question creates a rapport between you and the patients, and it makes her know that the doctor is ready to listen and help her.
What are you doing to cope with grief after losing your husband? This question will help the care ...
The presentation on How To Talk To Your Doctor discusses issues on what patients can do to get better medical care for themselves and at the same time making patients aware of their responsibility. The presentation was held at Health Education Library for People, Mumbai, India. For more information please log on to www.healthlibrary.com
Diagnosis and Treatment of Psychosomatic Disorder (Educational Slides)Andri Andri
This is a standard presentation for teaching medical students and colleagues about psychosomatic disorder, its diagnosis and therapy. We hope by reading this slides, you will understand the nature of psychosomatic disorder and its current approach in therapy
Geriatric Special Focus, Pain Management and Analgesic Prescribing for Advanc...Michelle Peck
Michelle Peck | Geriatric Nurse Practitioner | Health Care Consultant | Professional Speaker | Nursing Faculty| Legal Nurse Consultant | Mindful Geriatrics
In collaboration with Dr. Linh Nguyen, Supportive Medicine at UTHealth Medical School, we have created this slide deck for Advanced Practice Nurses.
Our mission is to simplify the pharmacologic basics of good pain prescribing. We have not provided very much detail about schedule II controlled substances due to the current limitations on Texas Nurse Practitioner prescribing in primary care.
This lecture is designed to meet our Advanced Practice Nursing audience where they are at and provide tools, knowledge and practical tips. Areas where we detect mastery with our polling questions are briefly touched upon and more time and examples are given are to areas of audience identified needs. Prescribing pain medication for Advanced Practice Nurses is dynamic, complex and ever changing
We have also included a special focus (our passion) for pain prescribing in the geriatric population. Beer’s Criteria medications, to be used with caution or avoid completely in geriatrics are mentioned throughout this presentation.
This presentation starts with the audience writing down their biggest fear about pain prescribing. We then categorize these fears, so that throughout our lecture we can give special focus and alleviate fears with practical tips, guidelines and real life examples.
Our objectives are to discuss:
1. Benefits and side effects of common analgesics
2. The impact of patient-related factors on drug selection & dose based on knowledge of patient related changes
3. Medications to avoid, use with caution, explain why
4. Management of pain based on client care goals
We hope you Learn it-Live it-Love it!
The Health Innovation Network Polypharmacy Programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Reducing opioid prescribing, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
Pharmacist Interventions and Medication Reviews at Care Homes - Improving Med...Health Innovation Wessex
The Health Innovation Network Polypharmacy Programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Pharmacist Interventions and Medication Reviews at Care Homes - Improving Medication Safety and Patient Outcomes, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
More Related Content
Similar to Medication Reviews—The Good, The Bad, and The Baffling Managing multiple medication: What do I want from you? by Sam Barnett-Cormack
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
NR 508 Enhance teaching - snaptutorial.comDavisMurphyA60
For more classes visit
www.snaptutorial.com
Discussion Part One
Emily, a relatively healthy 5’5”, 32-year-old young woman weighing 190 pounds, presents to your clinic with hirsutism, anovulation, oligomenorrhea, and at times amenorrhea. Biochemical blood tests reveal elevated luteinizing hormone (LH, without a mid-cycle surge) and androgen elevation.
Nr 508 Education Organization -- snaptutorial.comDavisMurphyC7
For more classes visit
www.snaptutorial.com
Discussion Part One
Emily, a relatively healthy 5’5”, 32-year-old young woman weighing 190 pounds, presents to your clinic with hirsutism, anovulation, oligomenorrhea, and at times amenorrhea. Biochemical blood tests reveal elevated
Nr 508 Education Redefined-snaptutorial.comrobertledwes48
For more classes visit
www.snaptutorial.com
Discussion Part One
Emily, a relatively healthy 5’5”, 32-year-old young woman weighing 190 pounds, presents to your clinic with hirsutism, anovulation, oligomenorrhea, and at times amenorrhea. Biochemical blood tests reveal elevated luteinizing hormone (LH, without a mid-cycle surge) and androgen elevation.
NR 508 Effective Communication - tutorialrank.comBartholomew49
For more course tutorials visit
www.tutorialrank.com
Discussion Part One
Emily, a relatively healthy 5’5”, 32-year-old young woman weighing 190 pounds, presents to your clinic with hirsutism, anovulation, oligomenorrhea, and at times amenorrhea. Biochemical blood tests reveal elevated luteinizing hormone (LH, without a mid-cycle surge) and androgen elevation.
For this Discussion, review the case Learning Resources and the DustiBuckner14
For this Discussion, review the case Learning Resources and the case study excerpt presented. Reflect on the case study excerpt and consider the therapy approaches you might take to assess, diagnose, and treat the patient’s health needs.
Case: An elderly widow who just lost her spouse.
Subjective: A patient presents to your primary care office today with chief complaint of insomnia. Patient is 75 YO with PMH of DM, HTN, and MDD. Her husband of 41 years passed away 10 months ago. Since then, she states her depression has gotten worse as well as her sleep habits. The patient has no previous history of depression prior to her husband’s death. She is awake, alert, and oriented x3. Patient normally sees PCP once or twice a year. Patient denies any suicidal ideations. Patient arrived at the office today by private vehicle. Patient currently takes the following medications:
•
Metformin 500mg BID
•
Januvia 100mg daily
•
Losartan 100mg daily
•
HCTZ 25mg daily
•
Sertraline 100mg daily
Current weight: 88 kg
Current height: 64 inches
Temp: 98.6 degrees F
BP: 132/86
By Day 3 of Week 7
Post
a response to each of the following:
• List three questions you might ask the patient if she were in your office. Provide a rationale for why you might ask these questions.
• Identify people in the patient’s life you would need to speak to or get feedback from to further assess the patient’s situation. Include specific questions you might ask these people and why.
• Explain what, if any, physical exams, and diagnostic tests would be appropriate for the patient and how the results would be used.
• List a differential diagnosis for the patient. Identify the one that you think is most likely and explain why.
• List two pharmacologic agents and their dosing that would be appropriate for the patient’s antidepressant therapy based on pharmacokinetics and pharmacodynamics. From a mechanism of action perspective, provide a rationale for why you might choose one agent over the other.
• For the drug therapy you select, identify any contraindications to use or alterations in dosing that may need to be considered based on the client’s ethnicity. Discuss why the contraindication/alteration you identify exists. That is, what would be problematic with the use of this drug in individuals of other ethnicities?
• Include any “check points” (i.e., follow-up data at Week 4, 8, 12, etc.), and indicate any therapeutic changes that you might make based on possible outcomes that may happen given your treatment options chosen.
Respond to the these discussions. All questions need to be addressed.
Discussion 1 En
Three questions to ask the patient and a rationale for asking these questions.
How may I be of assistance today? This question creates a rapport between you and the patients, and it makes her know that the doctor is ready to listen and help her.
What are you doing to cope with grief after losing your husband? This question will help the care ...
The presentation on How To Talk To Your Doctor discusses issues on what patients can do to get better medical care for themselves and at the same time making patients aware of their responsibility. The presentation was held at Health Education Library for People, Mumbai, India. For more information please log on to www.healthlibrary.com
Diagnosis and Treatment of Psychosomatic Disorder (Educational Slides)Andri Andri
This is a standard presentation for teaching medical students and colleagues about psychosomatic disorder, its diagnosis and therapy. We hope by reading this slides, you will understand the nature of psychosomatic disorder and its current approach in therapy
Geriatric Special Focus, Pain Management and Analgesic Prescribing for Advanc...Michelle Peck
Michelle Peck | Geriatric Nurse Practitioner | Health Care Consultant | Professional Speaker | Nursing Faculty| Legal Nurse Consultant | Mindful Geriatrics
In collaboration with Dr. Linh Nguyen, Supportive Medicine at UTHealth Medical School, we have created this slide deck for Advanced Practice Nurses.
Our mission is to simplify the pharmacologic basics of good pain prescribing. We have not provided very much detail about schedule II controlled substances due to the current limitations on Texas Nurse Practitioner prescribing in primary care.
This lecture is designed to meet our Advanced Practice Nursing audience where they are at and provide tools, knowledge and practical tips. Areas where we detect mastery with our polling questions are briefly touched upon and more time and examples are given are to areas of audience identified needs. Prescribing pain medication for Advanced Practice Nurses is dynamic, complex and ever changing
We have also included a special focus (our passion) for pain prescribing in the geriatric population. Beer’s Criteria medications, to be used with caution or avoid completely in geriatrics are mentioned throughout this presentation.
This presentation starts with the audience writing down their biggest fear about pain prescribing. We then categorize these fears, so that throughout our lecture we can give special focus and alleviate fears with practical tips, guidelines and real life examples.
Our objectives are to discuss:
1. Benefits and side effects of common analgesics
2. The impact of patient-related factors on drug selection & dose based on knowledge of patient related changes
3. Medications to avoid, use with caution, explain why
4. Management of pain based on client care goals
We hope you Learn it-Live it-Love it!
Similar to Medication Reviews—The Good, The Bad, and The Baffling Managing multiple medication: What do I want from you? by Sam Barnett-Cormack (20)
The Health Innovation Network Polypharmacy Programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Reducing opioid prescribing, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
Pharmacist Interventions and Medication Reviews at Care Homes - Improving Med...Health Innovation Wessex
The Health Innovation Network Polypharmacy Programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Pharmacist Interventions and Medication Reviews at Care Homes - Improving Medication Safety and Patient Outcomes, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
The Health Innovation Network Polypharmacy Programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, SBAR Patient Engagement Tool, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
The Health Innovation Network Polypharmacy Programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Reducing medication related falls risk in patients with severe frailty, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
The Health Innovation Network Polypharmacy Programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Assessing the outcomes of structured medication reviews, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
The Health Innovation Network Polypharmacy Programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Polypharmacy SMR reviews in outpatient bone health clinics, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
Polypharmacy reviews of asthma and COPD patients over 65 and 10 or more medic...Health Innovation Wessex
The Health Innovation Network Polypharmacy Programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Polypharmacy reviews of asthma and COPD patients over 65 and 10 or more medicines, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
Evaluating the impact of a specialist frailty multidisciplinary team pathway ...Health Innovation Wessex
The Health Innovation Network Polypharmacy Programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Evaluating the impact of a specialist frailty multidisciplinary team pathway with clinical pharmacist involvement, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
Genome UK – State of the nation by Professor Dame Sue Hill, Chief Scientific Officer for England and NHS Genomics Programme Senior Responsible Officer.
Pharmacogenomics into practice - stroke services and a systems approach by Dr Richard Marigold, Consultant Stroke Physician and NIHR Hyperacute Stroke Research Centre Lead, University Hospital Southampton NHS Foundation Trust
To evaluate the benefits of Structured Medication Reviews in elderly Chinese ...Health Innovation Wessex
The Health Innovation Network Polypharmacy programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, To evaluate the benefits of Structured Medication Reviews in elderly Chinese patients, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
The Health Innovation Network Polypharmacy programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary,
Review of patients on high dose opioids at Living Well PCN, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
The Health Innovation Network Polypharmacy programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Re-establishing autonomy in elderly frail patients, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
The Health Innovation Network Polypharmacy programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Improving Medication Reviews using the NO TEARS Tool, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
Improving care in County Durham under the STOMP agenda - A 5 year review.pdfHealth Innovation Wessex
The Health Innovation Network Polypharmacy programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Improving care in County Durham under the STOMP agenda - A 5 year review, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
Impact of an EMIS search to prioritise care home residents for a pharmacist l...Health Innovation Wessex
The Health Innovation Network Polypharmacy programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Impact of an EMIS search to prioritise care home residents for a pharmacist led medication review, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
The Health Innovation Network Polypharmacy programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Identifying Orthostatic Hypotension caused by Medication, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
This document is designed as an introductory to medical students,nursing students,midwives or other healthcare trainees to improve their understanding about how health system in Sri Lanka cares children health.
COVID-19 PCR tests remain a critical component of safe and responsible travel in 2024. They ensure compliance with international travel regulations, help detect and control the spread of new variants, protect vulnerable populations, and provide peace of mind. As we continue to navigate the complexities of global travel during the pandemic, PCR testing stands as a key measure to keep everyone safe and healthy. Whether you are planning a business trip, a family vacation, or an international adventure, incorporating PCR testing into your travel plans is a prudent and necessary step. Visit us at https://www.globaltravelclinics.com/
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Medication Reviews—The Good, The Bad, and The Baffling Managing multiple medication: What do I want from you? by Sam Barnett-Cormack
1. My Background
Patient Experiences of Medication Reviews
Take Home Points
Medication Reviews—The Good, The Bad,
and The Baffling
Managing multiple medication: What do I want from you?
Sam Barnett-Cormack
http://www.barnett-cormack.co.uk/
sam@barnett-cormack.co.uk
Tackling Polypharmacy: Stopping Medicines Safely
(July 2017)
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
2. My Background
Patient Experiences of Medication Reviews
Take Home Points
Outline
1 My Background
2 Patient Experiences of Medication Reviews
Let’s start with me. . .
Enduring mental health condition plus
Chronic pain with assorted other problems
Micro-scenarios
3 Take Home Points
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
3. My Background
Patient Experiences of Medication Reviews
Take Home Points
Education
Degrees:
BSc Mathematics and Computer Science (Lancaster, 2007)
MSc Advanced Computer Science (Lancaster, 2008)
MA Educational Research (Lancaster, 2014)
So what?
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
4. My Background
Patient Experiences of Medication Reviews
Take Home Points
Health
From early childhood: allergic eczema, asthma and rhinitis
From childhood: depressive episodes, later diagnosed as
Bipolar Disorder (type II)
From late teens: narcolepsy
Miscellaneous: migraine, irritable bowel syndrome,
mysterious balance problem
Some more recent developments:
Episode of serotonin syndrome due to medication
Eczema treated with immunosuppressants
B12 deficiency – idiopathic malabsorption
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
5. My Background
Patient Experiences of Medication Reviews
Take Home Points
Health – Impact
Disruption to education:
Frequent minor illnesses in childhood
About 10 weeks in psychiatric hospital during sixth form
Developed narcolepsy as an undergraduate – took seven
years to graduate
Developed other problems during MA
Mental health difficulties causing various problem in
employment as well as education
Life being complicated by medical appointments,
investigative procedures, treatments etc
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
6. My Background
Patient Experiences of Medication Reviews
Take Home Points
Experience representing patients
Contributed to or led several reports with the “Spartacus”
disability campaigning network.
Served on the Guideline Development Group and as a
topic specialist on the Quality Standards Advisory
Committee for the recent guideline and quality standard on
multimorbidity.
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
7. My Background
Patient Experiences of Medication Reviews
Take Home Points
Let’s start with me. . .
Enduring mental health condition plus
Chronic pain with assorted other problems
Micro-scenarios
What patients think going into reviews
“They want to take away my meds”
“What pointless bureaucracy. . . ”
“Maybe I can get them to take me off X”
“Oh dear, I’m going to have to explain everything again,
aren’t I?”
Feeling “exhausted, demeaned and anxious”
“I have better things to do with my time!”
“Oh good, I get to talk to that doctor. She really
understands me and listens.”
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
8. My Background
Patient Experiences of Medication Reviews
Take Home Points
Let’s start with me. . .
Enduring mental health condition plus
Chronic pain with assorted other problems
Micro-scenarios
About the “Case Studies”
We have three scenarios of patients and medication
reviews.
Apart from the first, these are not based on specific real
people.
They represent a synthesis of different patient experiences
intended to give a cross-section of positive and negative
experience.
As we don’t have a week to do this, they are far from
representative of the full range of patient experience.
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
9. My Background
Patient Experiences of Medication Reviews
Take Home Points
Let’s start with me. . .
Enduring mental health condition plus
Chronic pain with assorted other problems
Micro-scenarios
Me – Background
Hopefully you can remember the summary of my health,
but here’s a quick recap:
Allergies, eczema, asthma, rhinitis
Eczema treated with immunosuppressants
Bipolar II, previously diagnosed as depression
Narcolepsy
Migraine
IBS
Balance problem
B12 deficiency
Treatment for narcolepsy and immunosuppresant
treatment for eczema under shared care with neurology
and dermatology respectively.
Told I had to have the review before I could have more
repeat prescriptions
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
10. My Background
Patient Experiences of Medication Reviews
Take Home Points
Let’s start with me. . .
Enduring mental health condition plus
Chronic pain with assorted other problems
Micro-scenarios
The Review
Medications
Narcolepsy Modafinil
Eczema Azathioprine, steroid creams,
emollient creams, antimicrobials,
dressings
Asthma Combined fluticasone/salmeterol
inhaler, salbutamol inhaler
Allergies Chlorphenamine, fexofenadine
Bipolar Mirtazapine – no mood stabiliser
Migraines No prophylaxis – zolmitriptan or
ibuprofen (600-800mg) as needed
IBS Mebeverine
Balance Cinnarizine for occasional use
B12 Injections every 8 weeks
What happens at review?
Named GP on sabbatical, and
no GP felt comfortable
conducting review.
Had review with practice
pharmacist by telephone.
Long, in-depth review lasting
most of an hour.
As usual, questions raised about
having two antihistamines, and
the range of emollients in use.
Somewhat lacking in insight into
many conditions, however. . .
Gained some new insights into
digestive problems.
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
11. My Background
Patient Experiences of Medication Reviews
Take Home Points
Let’s start with me. . .
Enduring mental health condition plus
Chronic pain with assorted other problems
Micro-scenarios
Patient Reaction
Amused by GPs unfamiliar with my case being unwilling to
take it on – but also a little worried.
Impressed by knowledge of pharmacist.
Frustrated by continuing desire to reduce range of
emollients/antimicrobials in use, as it’s a well-established
and effective regime where each cream/ointment has its
own use.
Digestive symptoms improved by simple dietary
adjustment.
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
12. My Background
Patient Experiences of Medication Reviews
Take Home Points
Let’s start with me. . .
Enduring mental health condition plus
Chronic pain with assorted other problems
Micro-scenarios
Enduring mental health plus – Background
Alice has had asthma since childhood, well controlled
Diagnosed with psychosis in late teens
Experiences delusions, has previously become
non-compliant with asthma treatment due to these
On current antipsychotic medication for a year
Took up smoking as an in-patient
Has experienced significant weight gain since starting
antipsychotic treatment
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
13. My Background
Patient Experiences of Medication Reviews
Take Home Points
Let’s start with me. . .
Enduring mental health condition plus
Chronic pain with assorted other problems
Micro-scenarios
The Review
Medications
Asthma Beclometasone
inhaler, salbutamol inhaler,
formerly occasional use of
oral prednisolone
discontinued following
psychosis diagnosis
Psychosis Olanzapine
What happens at review?
GP hears about weight gain,
explains that this is not unusual with
olanzapine, advises mentioning it to
MH Service
Alice expresses interest in quitting
smoking, particularly in
pharmaceutical assistance, having
heard of “medicines that make you
stop wanting to smoke”
GP provides details of self-referral
cessation service, but expresses
concern about smoking cessation
destabilising Alice
GP generally seems uncomfortable
reviewing antipsychotic treatment.
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
14. My Background
Patient Experiences of Medication Reviews
Take Home Points
Let’s start with me. . .
Enduring mental health condition plus
Chronic pain with assorted other problems
Micro-scenarios
Patient Reaction
Alice makes initial contact with smoking cessation service,
arranging an appointment for a consultation as they recognise
that her case isn’t straightforward.
At CPN appointment Alice discusses weight gain and wish to try
quitting smoking. This is fortunate, as olanzapine interacts with
smoking, so dose adjustment may be necessary.
This had clearly not been adequately communicated – the GP
was not aware of this factor in relation to Alice’s medication, and
there had been no communication of her interest in smoking
cessation (or anything else) to MH services after the review.
Alice able to move forward cautiously with attempts to quit
smoking, gets advice about medication-related weight gain.
However, she doesn’t feel her healthcare is very “joined-up”.
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
15. My Background
Patient Experiences of Medication Reviews
Take Home Points
Let’s start with me. . .
Enduring mental health condition plus
Chronic pain with assorted other problems
Micro-scenarios
Background
Bob has chronic pain, and has been diagnosed with
fibromyalgia, as well as specific injuries from time to time.
The injuries always seem to take a long time to heal.
Particular areas of pain responded well to steroid
challenge, but no inflammatory condition could be
diagnosed.
He chooses when to take which of his painkillers, taking
codeine when pain is particularly bad. Current medication
leaves him in considerable pain frequently, but he doesn’t
take codeine most days.
Has had several episodes of iron deficiency anaemia.
Some depression, which Bob attributes to living with the
limitations his health imposes on him.
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
16. My Background
Patient Experiences of Medication Reviews
Take Home Points
Let’s start with me. . .
Enduring mental health condition plus
Chronic pain with assorted other problems
Micro-scenarios
The Review
Medications
Pain relief Gabapentin, plus
self-managed analgesia with
paracetamol, naproxen and
codeine
Depression/Fibromyalgia
Reboxetine
Anaemia Iron tablets on and
off for 2 years
What happens at review?
GP expresses concern about
Bob’s ongoing use of codeine.
Bob does not want to seem like
he’s insisting on opioids, but
sometimes nothing else does
much for the pain. He decides
not to ask for stronger pain relief.
GP notes repeated anaemia,
thinks of link to naproxen. Asked,
Bob reports occasional
abdominal pain.
GP offers a stomach protector
(PPI) and asks Bob to keep a
note of abdominal pain for early
review.
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
17. My Background
Patient Experiences of Medication Reviews
Take Home Points
Let’s start with me. . .
Enduring mental health condition plus
Chronic pain with assorted other problems
Micro-scenarios
Patient Reaction
Bob is disappointed regarding pain relief, but doesn’t feel
like he’ll be able to bring up the inadequacy of his pain
management without risking what relief he does have.
He is also worried about the abdominal pain, but reassured
that this may explain his anaemia and feels hopeful that
the PPI will take care of it.
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
18. My Background
Patient Experiences of Medication Reviews
Take Home Points
Let’s start with me. . .
Enduring mental health condition plus
Chronic pain with assorted other problems
Micro-scenarios
Micro-scenarios
As well as these detailed scenarios, here are a few shorter
scenarios to highlight some particular aspects of patient
experience.
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
19. My Background
Patient Experiences of Medication Reviews
Take Home Points
Let’s start with me. . .
Enduring mental health condition plus
Chronic pain with assorted other problems
Micro-scenarios
Reviews are compulsory, but not available
Carol takes medication for epilepsy (among others) and
only told they need a review when they chase up a repeat
prescription.
Told they can’t have any prescriptions until they have their
review.
Told there are no available appointments for over 2 weeks,
when they run out of epilepsy medication in one week.
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
20. My Background
Patient Experiences of Medication Reviews
Take Home Points
Let’s start with me. . .
Enduring mental health condition plus
Chronic pain with assorted other problems
Micro-scenarios
Medicines use reviews require expertise and attention
Dana takes, among other things, slow sodium tablets, and
is a smoker.
A pharmacist they have not had previous contact with
invites them for a medicines use review.
The pharmacist checks they know what their medicines are
for, and that they are comfortable taking them.
During general health questions, says “you don’t smoke,
do you?”. Dana is uncomfortable answering honestly.
Also during general health questions, is asked if she gets
“too much salt”. While Dana isn’t sure how much would be
too much, this seems a particularly odd question when
they just went through her medication – including slow
sodium tablets.
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
21. My Background
Patient Experiences of Medication Reviews
Take Home Points
Let’s start with me. . .
Enduring mental health condition plus
Chronic pain with assorted other problems
Micro-scenarios
What is the point of the review, and how is it best
served?
Eric has osteogenesis imperfecta, with collection of other
related and unrelated diagnoses.
Eric has strong opioid pain relief under the care of a pain
management clinic.
Reviews are conducted every 6 months.
Reviews are often with doctors that Eric hasn’t seen before.
Eric finds this a burdensome and largely pointless activity,
with extra anxiety each time it’s a new doctor.
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
22. My Background
Patient Experiences of Medication Reviews
Take Home Points
Let’s start with me. . .
Enduring mental health condition plus
Chronic pain with assorted other problems
Micro-scenarios
Sometimes we wonder about the point of our
medications
Francis takes a selection of pain relief much like Bob’s –
paracetamol, NSAID and opioid.
She’s been told that these are synergistic, each making the
other more effective. She is sceptical about this.
GP agrees that they often say this about painkillers, but it
doesn’t always work that way.
Francis and her GP agree to try dropping the paracetamol,
as that does nothing without the others anyway.
This makes no noticeable difference to her pain
management.
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
23. My Background
Patient Experiences of Medication Reviews
Take Home Points
Let’s start with me. . .
Enduring mental health condition plus
Chronic pain with assorted other problems
Micro-scenarios
Medicines use reviews redux
George has a medicines use review with his new
pharmacist. He is on several painkillers, and treatments for
migraines and other conditions.
The pharmacist seems uninterested in George’s
explanations of what each medicine is for, and focuses on
the painkillers.
The pharmacist goes on to suggest hot baths to help pain
as an alternative to medication, as well as various
alternative therapies, and some incomprehensible
quackery a friend used to manage migraines.
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
24. My Background
Patient Experiences of Medication Reviews
Take Home Points
Relationships and Communication
Patients are more positive about reviews when we trust the
professional in questions, and when we feel that they
know, understand, and trust us.
Dealing with a new doctor for a medication review can be
more challenging than dealing with a new doctor when we
have a new or changed symptom.
Only telling a patient they need a review when they request
a repeat prescription creates extra stress – especially if
you refuse the prescription until they have the review.
Where a patient has medications managed/prescribed by
secondary care, or under shared care, communication
between clinicians is vital. Too often we have to make sure
different services know what each other is doing.
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
25. My Background
Patient Experiences of Medication Reviews
Take Home Points
Manner and Delivery
Don’t make assumptions when you ask a question. Making it
clear which answer you want to hear (“you don’t smoke, do
you?”) does not encourage an honest answer.
Encouraging compliance is important, but compliance will rarely
be improved by the patient feeling bullied.
Patients aren’t all the same. A review should be co-produced by
doctor and patient, but what that takes will vary:
Some patients will rely on your expertise, and need careful
guidance to help them be involved in decisions.
Others are very engaged and knowledgeable about their options.
All of us are dependant on your information and expertise – don’t
just ask us what we want you to do without informing us.
It often seems like doctors want the patient to give a complete
history about each condition they have medication for. If you
can’t get this from the notes, please explain. If you can, please
do.
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
26. My Background
Patient Experiences of Medication Reviews
Take Home Points
Hopes and Fears
Many patients worry that you will try to take away important
medication, especially things like benzodiazepines and
opioids.
This is partly because of the rhetoric and discourse around
such drugs – stories of abuse, or restrictive prescribing
policies.
It’s also because of how devastating the impact of these
symptoms can be when untreated.
Talk about handling polypharmacy and deprescribing
makes this fear more acute for all medicines.
We can feel burdened volume of medicines. Simplification/
rationalisation is often attractive, especially if we believe
the aim is to get the same or better symptom control.
Sometimes we’re happy to stop taking something if it’s
probably not helping.
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
27. My Background
Patient Experiences of Medication Reviews
Take Home Points
Your Expertise
We rely on your expertise to spot possible interactions,
offer solutions, come up with ideas.
For those of us with complex medical lives, we know that
telling you about absolutely everything isn’t practical – and
even if we tried to, we would inevitably miss things out.
Ask about specific possible side effects – we don’t even
necessarily know, if something happens, whether it’s
related to a medication or to a new or existing condition.
We can get a bit jaded.
Done properly, medication reviews can be a really positive
experience, both medically and emotionally. Done poorly,
they discourage and alienate patients.
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling
28. My Background
Patient Experiences of Medication Reviews
Take Home Points
The End
http://www.
barnett-cormack.co.uk/
sam@barnett-cormack.co.uk
Sam Barnett-Cormack Medication Reviews—The Good, The Bad, and The Baffling